Search Results - "Allan, Elaine K"

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors by Pellicano, Francesca, Scott, Mary T., Helgason, G. Vignir, Hopcroft, Lisa E. M., Allan, Elaine K., Aspinall‐O'Dea, Mark, Copland, Mhairi, Pierce, Andrew, Huntly, Brian J. P., Whetton, Anthony D., Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR‐ABL which activates a number of signal transduction pathways, including…”
Get full text

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition by Mitchell, Rebecca, Hopcroft, Lisa E M, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O’Prey, Jim, Hair, Alan, Melo, Junia V, Chan, Edmond, Ryan, Kevin M, Maguer-Satta, Véronique, Druker, Brian J, Clark, Richard E, Mitra, Subir, Herzyk, Pawel, Nicolini, Franck E, Salomoni, Paolo, Shanks, Emma, Calabretta, Bruno, Holyoake, Tessa L, Helgason, G Vignir

Get full text

Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate by JØRGENSEN, Heather G, COPLAND, Mhairi, ALLAN, Elaine K, XIAOYAN JIANG, EAVES, Allen, EAVES, Connie, HOLYOAKE, Tessa L

“…Purpose: Primitive quiescent chronic myeloid leukemia (CML) cells are biologically resistant to imatinib mesylate, an inhibitor of the p210 BCR-ABL kinase. The…”
Get full text

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival by Hamilton, Ashley, Helgason, G. Vignir, Schemionek, Mirle, Zhang, Bin, Myssina, Svetlana, Allan, Elaine K., Nicolini, Franck E., Müller-Tidow, Carsten, Bhatia, Ravi, Brunton, Valerie G., Koschmieder, Steffen, Holyoake, Tessa L.

“…Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated…”
Get full text

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction by Copland, Mhairi, Hamilton, Ashley, Elrick, Lucy J., Baird, Janet W., Allan, Elaine K., Jordanides, Niove, Barow, Martin, Mountford, Joanne C., Holyoake, Tessa L.

“…Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and inhibits the majority of kinase…”
Get full text

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition by Mitchell, Rebecca, Hopcroft, Lisa E M, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O'Prey, Jim, Hair, Alan, Melo, Junia V, Chan, Edmond, Ryan, Kevin M, Maguer-Satta, Véronique, Druker, Brian J, Clark, Richard E, Mitra, Subir, Herzyk, Pawel, Nicolini, Franck E, Salomoni, Paolo, Shanks, Emma, Calabretta, Bruno, Holyoake, Tessa L, Helgason, G Vignir

“…Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of…”
Get full text

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation by Gallipoli, Paolo, Pellicano, Francesca, Morrison, Heather, Laidlaw, Kamilla, Allan, Elaine K., Bhatia, Ravi, Copland, Mhairi, Jørgensen, Heather G., Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) stem cells are not dependent on BCR-ABL kinase for their survival, suggesting that kinase-independent mechanisms must contribute…”
Get full text

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells by Jørgensen, Heather G., Allan, Elaine K., Jordanides, Niove E., Mountford, Joanne C., Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) stem and progenitor cells overexpress BcrAbl and are insensitive to imatinib mesylate (IM). We therefore investigated whether…”
Get full text

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors by Copland, Mhairi, Pellicano, Francesca, Richmond, Linda, Allan, Elaine K., Hamilton, Ashley, Lee, Francis Y., Weinmann, Roberto, Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the tyrosine kinase inhibitor imatinib…”
Get full text

ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells by Karvela, Maria, Baquero, Pablo, Kuntz, Elodie M., Mukhopadhyay, Arunima, Mitchell, Rebecca, Allan, Elaine K., Chan, Edmond, Kranc, Kamil R., Calabretta, Bruno, Salomoni, Paolo, Gottlieb, Eyal, Holyoake, Tessa L., Helgason, G. Vignir

“…A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated…”
Get full text

Poor performance of galactomannan and mannan sandwich enzyme‐linked immunosorbent assays in the diagnosis of invasive fungal infection by Allan, Elaine K., Jordanides, Niove E., McLintock, Lorna A., Copland, Mhairi, Devaney, Maureen, Stewart, Karen, Parker, Anne N., Johnson, Peter R.E., Holyoake, Tessa L., Jones, Brian L.

Get full text

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells by Heaney, Nicholas B., Pellicano, Francesca, Zhang, Bin, Crawford, Lisa, Chu, Su, Kazmi, Syed M.A., Allan, Elaine K., Jorgensen, Heather G., Irvine, Alexandra E., Bhatia, Ravi, Holyoake, Tessa L.

“…Chronic myeloid leukemia (CML) is treated effectively with tyrosine kinase inhibitors (TKIs); however, 2 key problems remain—the insensitivity of CML stem and…”
Get full text

α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571 by Jørgensen, Heather G., Elliott, Moira A., Allan, Elaine K., Carr, Christine E., Holyoake, Tessa L., Smith, Kevin D.

“…Despite the efficacy of STI571 (Glivec, Novartis, Basle, Switzerland) in treating chronic myeloid leukemia (CML), drug resistance has already been noted both…”
Get full text

Investigation into omacetaxine solution stability for in vitro study by Marenah, Lamin, Allan, Elaine K., Mountford, Joanne C., Holyoake, Tessa L., Jørgensen, Heather G., Elliott, Moira A.

“…ABSTRACT Omacetaxine is a natural product extract originating from Chinese medicine and finding therapeutic use as a potent myelosuppressive agent in leukemia…”
Get full text

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate by Jørgensen, Heather G., Allan, Elaine K., Mountford, Joanne C., Richmond, Linda, Harrison, Simon, Elliott, Moira A., Holyoake, Tessa L.

“…In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34 + cells without causing significant…”
Get full text

Fluorescence in situ hybridization for BCR-ABL by Drummond, Mark W, Allan, Elaine K, Pearce, Andrew, Holyoake, Tessa L

Get more information

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant by Erdmann, Robert, Jorgensen, Heather, Ben-Batalla, Isabel, Kruse, Nils, Micklem, David, von Amsberg, Gunhild, Schafhausen, Philippe, Schultze, Alexander, Wroblewski, Mark, Binder, Mascha, Cubas-Cordova, Miguel, Hadlich, Tobias, Janning, Melanie, Sawall, Stefanie, Gensch, Victoria, Allan, Elaine K, Mukherjee, Leena, Morrison, Heather, Cassells, Jennifer, Kroeger, Nicolaus, Lorens, James, Clark, Richard E., Koschmieder, Steffen, Vandenberghe, Peter, Brümmendorf, Tim H., Hochhaus, Andreas, Carmeliet, Peter, Holyoake, Tessa L., Pantel, Klaus, Bokemeyer, Carsten, Loges, Sonja

“…BCR-ABL1 inhibitors have revolutionized the treatment of CML patients. However several drawbacks remain, including clinical resistance of T315I-mutated CML…”
Get full text

Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML by Helgason, G.Vignir, Allan, Elaine K, Mariani, Samanta, Mukhopadhyay, Arunima, Karvela, Maria, Galavotti, Sara, Audia, Alessandra, Hamilton, Ashley, Nicolini, Franck E., Druker, Brian J., Salomoni, Paolo, Calabretta, Bruno, Holyoake, Tessa L.

“…Abstract 1664 Imatinib (IM), a tyrosine kinase inhibitor (TKI), represents the most successful targeted therapy in human cancer. However, this success has been…”
Get full text

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia by Erdmann, Robert, Jorgensen, Heather, Schultze, Alexander, von Amsberg, Gunhild, Ben-Battala, Isabel, Wroblewski, Mark, Cordova, Miguel Cubas, Sawall, Stefanie, Witzke, Victoria, Allan, Elaine K, Mukherjee, Leena, Morrison, Heather, Cassels, Jennifer, Schafhausen, Philippe, Kroeger, Nicolaus, Lorens, James, Clark, Richard E., Vandenberghe, Peter, Brümmendorf, Tim H., Hochhaus, Andreas, Carmeliet, Peter, Pantel, Klaus, Bokemeyer, Carsten, Holyoake, Tessa L., Loges, Sonja

“…BCR-ABL1 inhibitors have revolutionized treatment of CML patients. However several drawbacks remain, including therapy resistance of T315I-mutated CML and…”
Get full text

Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells by Irvine, David A, Zhang, Bin, Allan, Elaine K, Holyoake, Tessa L, Dorsch, Marion, Manley, Paul W, Bhatia, Ravi, Copland, Mhairi

“…Abstract 1428 Poster Board I-451 Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder arising in a hematopoietic stem cell (HSC). CML is…”
Get full text